Our results indicated that 10% (2/20) of very-early-onset (≤30 years) breast cancer patients with a family history of cancer carried a TP53 mutation, which is consistent with the results of Mouchawar et al. Since 2009, the NCCN guidelines have recommended that breast cancer patients who are diagnosed before the age of 30 and who are BRCA1/2 negative should also be offered genetic counseling and testing for TP53, in addition to those fulfilling LFS or LFL syndrome criteria. This evidence concerns the gene TP53 and breast carcinoma.